The FDA has licensed new 2025-2026 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax, mNEXSPIKE) and the adjuvanted protein subunit COVID-19 vaccine…
Med Lett Drugs Ther. 2025 Oct 13; 67(1739):166-8 doi:10.58347/tml.2025.1739d
The FDA has licensed new 2025-2026 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax, mNEXSPIKE) and the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax (Nuvaxovid) . The new formulations are indicated for use in all adults ≥65 years old and in persons 6 months (Spikevax) , 5 years (Comirnaty) , or 12 years (mNEXSPIKE, Nuvaxovid) through 64 years old who are at high risk for severe COVID-19 because of an underlying condition. An Emergency Use Authorization allowing administration of the Pfizer vaccine to children 6 months through 4 years old has been withdrawn.
The FDA has licensed mNEXSPIKE (Moderna), an mRNA vaccine, for prevention of COVID-19 in adults ≥65 years old and in persons 12-64 years old who have a condition that puts them at high risk for severe…
Med Lett Drugs Ther. 2025 Jul 21; 67(1733):119-20 doi:10.58347/tml.2025.1733h
The FDA has licensed mNEXSPIKE (Moderna), an mRNA vaccine, for prevention of COVID-19 in adults ≥65 years old and in persons 12-64 years old who have a condition that puts them at high risk for severe outcomes from COVID-19. Spikevax , the original Moderna mRNA COVID-19 vaccine, remains in production2; it is licensed for use in persons ≥12 years old and is available under an Emergency Use Authorization (EUA) for children 6 months to 11 years old.
The FDA has required the manufacturers of the mRNA COVID-19 vaccines Comirnaty (Pfizer-BioNTech) and Spikevax (Moderna) to revise their labels to include updated information about the risks of…
Med Lett Drugs Ther. 2025 Jul 21; 67(1733):119 doi:10.58347/tml.2025.1733g
The FDA has required the manufacturers of the mRNA COVID-19 vaccines Comirnaty (Pfizer-BioNTech) and Spikevax (Moderna) to revise their labels to include updated information about the risks of myocarditis/pericarditis. The FDA requested that the manufacturers submit the proposed labeling changes or contest the agency's requirement for the safety update by May 17, 2025. As of June 4th, to our knowledge, the labels of Comirnaty and Spikevax have not been updated and neither manufacturer has submitted a rebuttal.
Nuvaxovid , the adjuvanted protein subunit COVID-19 vaccine marketed by Novavax, has received full approval from the FDA to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2…
Med Lett Drugs Ther. 2025 Jul 21; 67(1733):118-9 doi:10.58347/tml.2025.1733f
Nuvaxovid , the adjuvanted protein subunit COVID-19 vaccine marketed by Novavax, has received full approval from the FDA to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in all adults ≥65 years old and in adults 12-64 years old who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. The vaccine was previously available under an FDA Emergency Use Authorization (EUA) for use in persons ≥12 years old.1 Nuvaxovid is the first protein-based COVID-19 vaccine to receive full approval from the FDA; the mRNA COVID-19 vaccines Comirnaty and Spikevax are approved for use in patients ≥12 years old.
According to the Centers for Disease Control (CDC), as of April 24 there have been 844 confirmed cases of measles in the US in 2025; 11% of cases have resulted in hospitalization and 3 patients have died. The…
Med Lett Drugs Ther. 2025 Jun 9; 67(1730):94-5 doi:10.58347/tml.2025.1730d
According to the Centers for Disease Control (CDC), as of April 24 there have been 844 confirmed cases of measles in the US in 2025; 11% of cases have resulted in hospitalization and 3 patients have died. The majority of cases (96%) have been in unvaccinated persons or in those whose vaccination history was unknown
The FDA has licensed the pentavalent vaccine Penmenvy (GSK) for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old.…
Med Lett Drugs Ther. 2025 Apr 14; 67(1726):57-9 doi:10.58347/tml.2025.1726a
The FDA has licensed the pentavalent vaccine Penmenvy (GSK) for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old. Penmenvy is the second pentavalent meningococcal vaccine to become available in the US; Penbraya was licensed in 2023.
The FDA has required a new warning in the labels of the recombinant respiratory syncytial virus (RSV) vaccines Arexvy (GSK) and Abrysvo (Pfizer) about an increased risk of Guillain-Barré syndrome (GBS) within…
Med Lett Drugs Ther. 2025 Feb 17; 67(1722):31-2 doi:10.58347/tml.2025.1722d
The FDA has required a new warning in the labels of the recombinant respiratory syncytial virus (RSV) vaccines Arexvy (GSK) and Abrysvo (Pfizer) about an increased risk of Guillain-Barré syndrome (GBS) within 42 days of administration of either vaccine. Both vaccines are FDA-approved to prevent lower respiratory tract disease (LRTD) caused by RSV in adults. Abrysvo is also approved for use in pregnant women at 32-36 weeks' gestation to prevent RSV-associated LRTD in their infants from birth through 6 months of age.
FluMist (AstraZeneca), the live-attenuated intranasal influenza vaccine that has been available for years for administration by a healthcare provider in nonpregnant persons 2-49 years old, has now been…
Med Lett Drugs Ther. 2024 Oct 28; 66(1714):174-5 doi:10.58347/tml.2024.1714c
FluMist (AstraZeneca), the live-attenuated intranasal influenza vaccine that has been available for years for administration by a healthcare provider in nonpregnant persons 2-49 years old, has now been approved by the FDA for self- or caregiver-administration. It is expected to be available for such use during the 2025-2026 influenza season. FluMist is only available through a healthcare provider this season. It will continue to be available for administration by a healthcare provider in the future
The FDA has licensed Capvaxive (PCV21; Merck), a 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia in adults. Four other pneumococcal…
Med Lett Drugs Ther. 2024 Oct 14; 66(1713):161-3 doi:10.58347/tml.2024.1713a
The FDA has licensed Capvaxive (PCV21; Merck), a 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia in adults. Four other pneumococcal vaccines are currently available in the US: Prevnar 20 (PCV20), Vaxneuvance (PCV15), and Prevnar 13 (PCV13) are conjugate vaccines licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23) is a pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years old (see Table 1).
TThe FDA has licensed mResvia (Moderna), an mRNA respiratory syncytial virus (RSV) vaccine, for prevention of lower respiratory tract disease (LRTD) caused by RSV in adults ≥60 years old. It is the first…
Med Lett Drugs Ther. 2024 Oct 14; 66(1713):166-8 doi:10.58347/tml.2024.1713d
TThe FDA has licensed mResvia (Moderna), an mRNA respiratory syncytial virus (RSV) vaccine, for prevention of lower respiratory tract disease (LRTD) caused by RSV in adults ≥60 years old. It is the first mRNA vaccine to be licensed in the US for this indication. Two recombinant RSV vaccines, Arexvy and Abrysvo , are also available for prevention of RSV LRTD. Arexvy is approved for use in adults ≥50 years old. Abrysvo is approved for use in adults ≥60 years old and in pregnant women to prevent RSV LRTD in their infants.
A reader of our article on the 2024-2025 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) asked us to provide more information on the data that…
Med Lett Drugs Ther. 2024 Oct 14; 66(1713):e168 doi:10.58347/tml.2024.1713h
A reader of our article on the 2024-2025 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) asked us to provide more information on the data that supported their licensure.
New 2024-2025 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) that more closely target currently circulating variants have been licensed by the FDA…
Med Lett Drugs Ther. 2024 Sep 16; 66(1711):151-2 doi:10.58347/tml.2024.1711c
New 2024-2025 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) that more closely target currently circulating variants have been licensed by the FDA for persons ≥12 years old and made available under FDA Emergency Use Authorizations (EUAs) for use in persons 6 months to 11 years old.1-3 A 2024-2025 formulation of the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax is expected to become available soon for persons ≥12 years old.
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD…
Med Lett Drugs Ther. 2024 Sep 2; 66(1710):137-44 doi:10.58347/tml.2024.1710a
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
A new 2023-2024 formulation of the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax that was developed to more closely target currently circulating SARS-CoV-2 variants has been made…
Med Lett Drugs Ther. 2023 Nov 13; 65(1689):182-3 doi:10.58347/tml.2023.1689b
A new 2023-2024 formulation of the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax that was developed to more closely target currently circulating SARS-CoV-2 variants has been made available in the US under an FDA Emergency Use Authorization (EUA) for use in persons ≥12 years old. The original formulation of the Novavax vaccine is no longer authorized for use in the US. In September, updated formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) were licensed by the FDA for use in persons ≥12 years old and made available under EUAs for use in persons 6 months to 11 years old.
In our article in issue 1687 on the updated 2023-2024 COVID-19 vaccines from Pfizer and Moderna (Med Lett Drugs Ther 2023; 65:161), the doses and formulations of the Pfizer vaccine were incorrect. A revised…
Med Lett Drugs Ther. 2023 Nov 13; 65(1689):184 doi:10.58347/tml.2023.1689d
In our article in issue 1687 on the updated 2023-2024 COVID-19 vaccines from Pfizer and Moderna (Med Lett Drugs Ther 2023; 65:161), the doses and formulations of the Pfizer vaccine were incorrect. A revised table has been posted in the online version of the article.
New 2023-2024 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and that more closely target currently circulating variants have been licensed by the FDA for use in persons…
Med Lett Drugs Ther. 2023 Oct 16; 65(1687):167-8 doi:10.58347/tml.2023.1687c
New 2023-2024 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and that more closely target currently circulating variants have been licensed by the FDA for use in persons ≥12 years old and made available under FDA Emergency Use Authorizations (EUAs) for use in persons 6 months to 11 years old. The bivalent (original and Omicron BA.4/5) formulations of the Pfizer and Moderna vaccines are no longer authorized for use in the US.
Two recombinant vaccines, Arexvy (GSK) and Abrysvo (Pfizer), have been approved by the FDA for prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults ≥60…
Med Lett Drugs Ther. 2023 Oct 2; 65(1686):153-6 doi:10.58347/tml.2023.1686a
Two recombinant vaccines, Arexvy (GSK) and Abrysvo (Pfizer), have been approved by the FDA for prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults ≥60 years old. They are the first RSV vaccines to be approved in the US. Abrysvo is also approved for use in pregnant women at 32-36 weeks' gestation to prevent LRTD caused by RSV in their infants from birth through 6 months of age.
The FDA has expanded its Emergency Use Authorization (EUA) for the COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) to permit use of the bivalent formulation (containing mRNA from the original and…
Med Lett Drugs Ther. 2023 Apr 17; 65(1674):63-4 doi:10.58347/tml.2023.1674c
The FDA has expanded its Emergency Use Authorization (EUA) for the COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) to permit use of the bivalent formulation (containing mRNA from the original and BA.4/5 Omicron strains of SARS-CoV-2) as a booster dose in children 6 months to 4 years old who completed the primary series with 3 doses of the monovalent formulation ≥2 months previously. The Pfizer bivalent vaccine had previously been authorized for use as a booster dose in persons ≥5 years old and as a third primary dose in children 6 months to 4 years old. Booster doses of the Moderna bivalent COVID-19 vaccine (Spikevax) for children 6 months to 5 years old were authorized earlier.
The FDA has expanded its Emergency Use Authorizations (EUAs) for the COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of the bivalent formulations of these…
Med Lett Drugs Ther. 2022 Dec 12; 64(1665):e209-10
The FDA has expanded its Emergency Use Authorizations (EUAs) for the COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of the bivalent formulations of these products (containing mRNA from the original and BA.4/5 Omicron strains of SARS-CoV-2) in children as young as 6 months. The bivalent Pfizer vaccine is authorized for use as the final dose of a 3-dose primary series in children 6 months to 4 years old. The bivalent Moderna vaccine is authorized for use as a booster dose in children 6 months to 5 years old who completed a primary series with the monovalent Moderna vaccine.1 Bivalent vaccines had previously been authorized for use as a booster dose in persons ≥5 years old (Pfizer) or ≥6 years old (Moderna).
The FDA has expanded its Emergency Use Authorization for the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax to include its use as a first booster dose in adults who completed a primary…
Med Lett Drugs Ther. 2022 Oct 31; 64(1662):e1-2
The FDA has expanded its Emergency Use Authorization for the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax to include its use as a first booster dose in adults who completed a primary series with any COVID-19 vaccine ≥6 months previously and are unable or unwilling to receive a booster dose of a bivalent mRNA vaccine. The Novavax vaccine is not authorized for use in persons who have received a booster dose of any other COVID-19 vaccine.
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these…
Med Lett Drugs Ther. 2022 Oct 17; 64(1661):161-8
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
The FDA has expanded its Emergency Use Authorizations (EUAs) for the COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of the bivalent formulations of these…
Med Lett Drugs Ther. 2022 Oct 17; 64(1661):e1
The FDA has expanded its Emergency Use Authorizations (EUAs) for the COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of the bivalent formulations of these products (containing mRNA from the original and BA.4/5 Omicron strains of SARS-CoV-2) as a booster dose in children as young as 5 years old (Pfizer) or 6 years old (Moderna). The bivalent Pfizer vaccine had previously been authorized for use in persons ≥12 years old and the bivalent Moderna vaccine in persons ≥18 years old. Bivalent vaccines are not authorized for primary immunization against COVID-19. The monovalent Pfizer and Moderna COVID-19 vaccines are no longer authorized for use as booster doses in any age group.
The FDA has amended its Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of bivalent formulations of the…
Med Lett Drugs Ther. 2022 Oct 3; 64(1660):159-60
The FDA has amended its Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of bivalent formulations of the products as a single booster dose in persons ≥12 years old (Pfizer) or ≥18 years old (Moderna) whose most recent COVID-19 vaccine dose was a monovalent product given ≥2 months previously as a booster or for completion of a primary series. The bivalent formulations are not authorized for primary immunization. Monovalent Pfizer and Moderna COVID-19 vaccines are no longer authorized for use as booster doses in persons ≥12 years old.
The FDA has expanded its Emergency Use Authorization for the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax to include use of the vaccine as a two-dose primary series in adolescents 12-17…
Med Lett Drugs Ther. 2022 Oct 3; 64(1660):e160
The FDA has expanded its Emergency Use Authorization for the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax to include use of the vaccine as a two-dose primary series in adolescents 12-17 years old. The vaccine was authorized for primary immunization of adults in July 2022.
An outbreak of monkeypox has recently spread around the globe and across the US. Updated information about the current outbreak is available from the CDC.
Med Lett Drugs Ther. 2022 Sep 5; 64(1658):137-9
An outbreak of monkeypox has recently spread around the globe and across the US. Updated information about the current outbreak is available from the CDC.
The FDA has issued an Emergency Use Authorization (EUA) for an adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax. The vaccine is indicated for use as a two-dose primary series to prevent…
Med Lett Drugs Ther. 2022 Aug 8; 64(1656):121-2
The FDA has issued an Emergency Use Authorization (EUA) for an adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax. The vaccine is indicated for use as a two-dose primary series to prevent COVID-19 in adults; it is not authorized for use in children or as a booster dose. Three other COVID-19 vaccines are available in the US for primary immunization of adults; the mRNA vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) are FDA-licensed for this indication, and the adenovirus-based vaccine manufactured by Johnson & Johnson (Janssen) is available under an EUA for use in adults who are unable or unwilling to receive another COVID-19 vaccine.
The FDA has expanded its Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to allow for their use in children as young as 6…
Med Lett Drugs Ther. 2022 Jul 11; 64(1654):110-2
The FDA has expanded its Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to allow for their use in children as young as 6 months old. The Pfizer vaccine was previously authorized for use in persons ≥5 years old, and the Moderna vaccine was authorized for use in adults ≥18 years old.
The FDA has expanded its Emergency Use Authorization for the mRNA COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) to include administration of a booster dose in children 5-11 years old who…
Med Lett Drugs Ther. 2022 Jun 13; 64(1652):94
The FDA has expanded its Emergency Use Authorization for the mRNA COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) to include administration of a booster dose in children 5-11 years old who completed a primary series of the Pfizer vaccine ≥5 months previously.
The FDA has restricted its Emergency Use Authorization for the adenovirus-based COVID-19 vaccine manufactured by Johnson & Johnson (Janssen) to adults who are unable or unwilling to receive another COVID-19…
Med Lett Drugs Ther. 2022 Jun 13; 64(1652):94-5
The FDA has restricted its Emergency Use Authorization for the adenovirus-based COVID-19 vaccine manufactured by Johnson & Johnson (Janssen) to adults who are unable or unwilling to receive another COVID-19 vaccine. The mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) are preferred for all persons without a contraindication.
The FDA has licensed PreHevbrio (VBI Vaccines), a recombinant, 3-antigen, 3-dose hepatitis B vaccine, for the prevention of infection caused by all known subtypes of hepatitis B virus (HBV) in adults. It has…
Med Lett Drugs Ther. 2022 May 16; 64(1650):73-5
The FDA has licensed PreHevbrio (VBI Vaccines), a recombinant, 3-antigen, 3-dose hepatitis B vaccine, for the prevention of infection caused by all known subtypes of hepatitis B virus (HBV) in adults. It has been available in Israel since 2000.
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) to allow for their use as a second booster dose…
Med Lett Drugs Ther. 2022 Apr 18; 64(1648):63-4
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) to allow for their use as a second booster dose ≥4 months after a first booster dose in adults ≥50 years old and in persons aged ≥12 years (Pfizer) or ≥18 years (Moderna) who have undergone solid organ transplantation or have a condition that compromises the immune system to a similar extent.
The CDC has issued new guidance allowing for an interval of up to 8 weeks between the first and second primary doses of an mRNA COVID-19 vaccine in certain patients 12-64 years old.1 Product labeling currently…
Med Lett Drugs Ther. 2022 Mar 21; 64(1646):47-8
The CDC has issued new guidance allowing for an interval of up to 8 weeks between the first and second primary doses of an mRNA COVID-19 vaccine in certain patients 12-64 years old.1 Product labeling currently recommends a 3-week interval between the first two doses of the Pfizer/BioNTech mRNA vaccine (Comirnaty) and a 4-week interval between the first two doses of the Moderna mRNA vaccine (Spikevax) . The new guidance is based on data suggesting that a longer interval can decrease the risk of myocarditis and may improve vaccine efficacy.
On January 3, the FDA amended its Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) to incorporate the following changes. The anti-SARS-CoV-2 antibody combinations…
Med Lett Drugs Ther. 2022 Jan 24; 64(1642):16
On January 3, the FDA amended its Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) to incorporate the following changes. The anti-SARS-CoV-2 antibody combinations casirivimab plus imdevimab (REGEN-COV) and bamlanivimab plus etesevimab are not active against the Omicron variant of SARS-CoV-2.
On November 19, the FDA expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to include administration of a…
Med Lett Drugs Ther. 2021 Dec 27; 63(1640):201-2
On November 19, the FDA expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to include administration of a booster dose for all adults ≥18 years old after primary immunization with either the same COVID-19 vaccine or a different one. Booster doses of these vaccines were previously authorized only for select populations (age ≥65 years or persons at high risk for severe COVID-19). The EUA for the adenovirus-based vaccine manufactured by Johnson & Johnson was amended in October 2021 to include administration of a booster dose for all adults ≥18 years old after primary immunization with the Johnson & Johnson vaccine.
The FDA has issued an Emergency Use Authorization (EUA) for a lower-strength (10 mcg/0.2 mL) formulation of the mRNA-based COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) for use in children 5-11…
Med Lett Drugs Ther. 2021 Nov 29; 63(1638):185
The FDA has issued an Emergency Use Authorization (EUA) for a lower-strength (10 mcg/0.2 mL) formulation of the mRNA-based COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) for use in children 5-11 years old. The original formulation of (Comirnaty) (30 mcg/0.3 mL) is FDA-licensed for use in persons ≥16 years old and available under an EUA for use in adolescents 12-15 years old.
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) and the adenovirus-based vaccine…
Med Lett Drugs Ther. 2021 Nov 29; 63(1638):186-8
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) and the adenovirus-based vaccine manufactured by Johnson & Johnson/Janssen to include administration of a booster dose in select populations after primary immunization with either the same COVID-19 vaccine or a different one.
The FDA has licensed two new pneumococcal conjugate vaccines (PCVs) for prevention of invasive pneumococcal disease in adults: Prevnar 20 (PCV20; Pfizer), which contains antigens from 20 serotypes of…
Med Lett Drugs Ther. 2021 Nov 29; 63(1638):188-90
The FDA has licensed two new pneumococcal conjugate vaccines (PCVs) for prevention of invasive pneumococcal disease in adults: Prevnar 20 (PCV20; Pfizer), which contains antigens from 20 serotypes of pneumococcus, and Vaxneuvance (PCV15; Merck), which contains antigens from 15 serotypes. Two other pneumococcal vaccines are available in the US: Prevnar 13 (PCV13; Pfizer), a 13-valent conjugate vaccine licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23; Merck), a 23-valent pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years old.
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were…
Med Lett Drugs Ther. 2021 Nov 15; 63(1637):177-84
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
On September 22, on the advice of its Vaccines and Related Biologic Products Advisory Committee, the FDA expanded the Emergency Use Authorization (EUA) for the Pfizer/BioNTech mRNA-based COVID-19 vaccine…
Med Lett Drugs Ther. 2021 Oct 18; 63(1635):161-2
On September 22, on the advice of its Vaccines and Related Biologic Products Advisory Committee, the FDA expanded the Emergency Use Authorization (EUA) for the Pfizer/BioNTech mRNA-based COVID-19 vaccine (Comirnaty) to include administration of a booster dose ≥6 months after a 2-dose primary series in adults who are ≥65 years old or at high risk for severe COVID-19 because of an underlying medical condition or frequent institutional or occupational exposure to SARS-CoV-2 (see Table 1). The FDA Advisory Committee recommended against authorization of a booster dose of Comirnaty for all persons ≥16 years old, citing a lack of adequate data.
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to include administration of a third dose in…
Med Lett Drugs Ther. 2021 Sep 20; 63(1633):145-6
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to include administration of a third dose in persons ≥12 years old (Pfizer/BioNTech) or ≥18 years old (Moderna) who have undergone solid organ transplantation or have a condition that compromises the immune system to a similar extent (see Table 1).
The FDA has licensed the adjuvanted, recombinant varicella zoster virus (VZV) vaccine Shingrix (GSK) for prevention of herpes zoster (shingles) in adults of any age who are or will be at elevated risk because…
Med Lett Drugs Ther. 2021 Aug 23; 63(1631):129
The FDA has licensed the adjuvanted, recombinant varicella zoster virus (VZV) vaccine Shingrix (GSK) for prevention of herpes zoster (shingles) in adults of any age who are or will be at elevated risk because of disease- or therapy-induced immunodeficiency or immunosuppression. Shingrix has been licensed for herpes zoster prevention in adults ≥50 years old since 2017.1 It is the only VZV vaccine currently available in the US; Zostavax , a live-attenuated VZV vaccine, was withdrawn from the market in 2020.
The investigational monoclonal antibodies casirivimab and imdevimab ( REGEN-COV – Regeneron) have been available in the US under an Emergency Use Authorization (EUA) since late 2020 for use together to treat…
Med Lett Drugs Ther. 2021 Aug 23; 63(1631):130-1
The investigational monoclonal antibodies casirivimab and imdevimab ( REGEN-COV – Regeneron) have been available in the US under an Emergency Use Authorization (EUA) since late 2020 for use together to treat mild to moderate COVID-19 in persons ≥12 years old who weigh ≥40 kg and are at high risk of progression to severe disease or hospitalization. The FDA has now expanded this EUA to allow use of the antibodies together for post-exposure prophylaxis of COVID-19 in such persons, if they are not fully vaccinated against COVID-19 or are unlikely to have an adequate immune response to full vaccination and have been in close contact with a SARS-CoV-2-infected individual or are likely to be exposed to SARS-CoV-2 in the setting of an institutional outbreak (see Table 1). Casirivimab and imdevimab are the first drugs to receive an EUA for post-exposure prophylaxis of COVID-19.
On July 12, 2021, the FDA added a warning to the Fact Sheet for the Johnson & Johnson (Janssen) adenovirus-based COVID-19 vaccine about an increased risk of Guillain-Barré syndrome (GBS) following…
Med Lett Drugs Ther. 2021 Aug 9; 63(1630):121
On July 12, 2021, the FDA added a warning to the Fact Sheet for the Johnson & Johnson (Janssen) adenovirus-based COVID-19 vaccine about an increased risk of Guillain-Barré syndrome (GBS) following administration of the product.
On May 10, 2021, the FDA expanded its Emergency Use Authorization (EUA) for the Pfizer/BioNTech mRNA-based COVID-19 vaccine to include adolescents 12-15 years old.1The vaccine has been authorized for use in…
Med Lett Drugs Ther. 2021 May 31; 63(1625):81
On May 10, 2021, the FDA expanded its Emergency Use Authorization (EUA) for the Pfizer/BioNTech mRNA-based COVID-19 vaccine to include adolescents 12-15 years old.1The vaccine has been authorized for use in persons ≥16 years old since December 2020.
On April 23, 2021, on advice from the Advisory Committee on Immunization Practices (ACIP), the FDA and CDC recommended that use of the Johnson & Johnson adenovirus-based COVID-19 vaccine resume despite its…
Med Lett Drugs Ther. 2021 May 17; 63(1624):e1
On April 23, 2021, on advice from the Advisory Committee on Immunization Practices (ACIP), the FDA and CDC recommended that use of the Johnson & Johnson adenovirus-based COVID-19 vaccine resume despite its association with development of thrombosis with thrombocytopenia syndrome (TTS). Administration of the vaccine had been paused on April 13 because of 6 reports of TTS, but after completing a data review that identified a further 9 cases associated with the formulation, the agencies concluded that the benefits of the vaccine outweighed its risks. About 7.98 million doses of the single-dose vaccine had been administered in the US at the time of the review.
On April 13, 2021, the FDA and CDC advised suspending use of the Johnson & Johnson adenovirus-based COVID-19 vaccine while the agencies investigate 6 cases of cerebral venous sinus thrombosis (CVST) and…
Med Lett Drugs Ther. 2021 May 3; 63(1623):e1
On April 13, 2021, the FDA and CDC advised suspending use of the Johnson & Johnson adenovirus-based COVID-19 vaccine while the agencies investigate 6 cases of cerebral venous sinus thrombosis (CVST) and thrombocytopenia that occurred following administration of the vaccine. In an April 14 emergency meeting, the Advisory Committee on Immunization Practices (ACIP) recommended continuing the suspension until more data become available. About 7 million people in the US have received the Johnson & Johnson vaccine.
On February 27, 2021, the FDA issued an Emergency Use Authorization (EUA) for the Johnson & Johnson adenovirus-based vaccine for prevention of COVID-19 in persons ≥18 years old. It is the third COVID-19…
Med Lett Drugs Ther. 2021 Mar 22; 63(1620):41-2
On February 27, 2021, the FDA issued an Emergency Use Authorization (EUA) for the Johnson & Johnson adenovirus-based vaccine for prevention of COVID-19 in persons ≥18 years old. It is the third COVID-19 vaccine to become available in the US and the first to require only a single dose. Two-dose mRNA-based vaccines manufactured by Pfizer-BioNTech and Moderna received EUAs in December 2020.
On December 18, 2020, the FDA issued an Emergency Use Authorization (EUA) for the Moderna mRNA-based vaccine for prevention of COVID-19 in persons ≥18 years old. The Pfizer-BioNTech mRNA-based vaccine…
Med Lett Drugs Ther. 2021 Jan 25; 63(1616):9-10
On December 18, 2020, the FDA issued an Emergency Use Authorization (EUA) for the Moderna mRNA-based vaccine for prevention of COVID-19 in persons ≥18 years old. The Pfizer-BioNTech mRNA-based vaccine received an FDA EUA for the same indication in persons ≥16 years old on December 11, 2020.
The FDA has issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA-based vaccine for prevention of COVID-19 in persons ≥16 years old.
Med Lett Drugs Ther. 2021 Jan 11; 63(1615):1-2
The FDA has issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA-based vaccine for prevention of COVID-19 in persons ≥16 years old.
The Advisory Committee on Immunization Practices (ACIP) has issued new recommendations for meningococcal vaccination. Booster vaccination against Neisseria meningitidis serogroup B (MenB) is now recommended in…
Med Lett Drugs Ther. 2020 Nov 30; 62(1612):191-2
The Advisory Committee on Immunization Practices (ACIP) has issued new recommendations for meningococcal vaccination. Booster vaccination against Neisseria meningitidis serogroup B (MenB) is now recommended in persons at increased risk for meningococcal disease (see Table 1). MenB booster doses were not recommended previously for any population.
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and…
Med Lett Drugs Ther. 2020 Sep 7; 62(1606):137-44
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and review articles on COPD treatment have been published in recent years. Treatment of acute exacerbations is not discussed here.
Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.
Med Lett Drugs Ther. 2019 Oct 7; 61(1582):153-60
Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.
Persons planning to travel outside the US should be up to date on routine vaccines and, depending on their destination, duration of travel, and planned activities, may also receive certain travel-specific…
Med Lett Drugs Ther. 2018 Nov 19; 60(1560):185-92
Persons planning to travel outside the US should be up to date on routine vaccines and, depending on their destination, duration of travel, and planned activities, may also receive certain travel-specific vaccines. Tickborne encephalitis and dengue vaccines, which are not available in the US, are reviewed in a separate article available online. Detailed advice for travel to specific destinations is available from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/travel/destinations/list. Recommendations for administration of vaccines as part of routine adult immunization are discussed in a separate issue.
The recommendations for treatment of varicella-zoster virus (VZV) and herpes simplex virus (HSV) infections are listed in tables 1 and 2. Vaccination against VZV was reviewed in a previous issue.
Med Lett Drugs Ther. 2018 Sep 24; 60(1556):153-7
The recommendations for treatment of varicella-zoster virus (VZV) and herpes simplex virus (HSV) infections are listed in tables 1 and 2. Vaccination against VZV was reviewed in a previous issue.
The US Advisory Committee on Immunization Practices (ACIP) recommends routine use of the following vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with…
Med Lett Drugs Ther. 2018 May 7; 60(1546):73-82
The US Advisory Committee on Immunization Practices (ACIP) recommends routine use of the following vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with acellular pertussis (Tdap), measles/mumps/rubella (MMR), varicella (VAR), herpes zoster (RZV; ZVL), human papillomavirus (HPV), and pneumococcal conjugate (PCV13) and polysaccharide (PPSV23) vaccines. For adults with certain medical conditions or occupational, behavioral, or other risk factors, hepatitis A (HepA), hepatitis B (HepB), meningococcal (MenACWY; MenB), and Haemophilus influenzae type b (Hib) vaccines are also recommended. Recommendations for vaccination against seasonal influenza and vaccination of travelers are reviewed separately.
The FDA has approved a two-dose hepatitis B virus (HBV) vaccine ( Heplisav-B – Dynavax) for use in adults ≥18 years old. The three other HBV vaccines marketed in the US are usually administered in 3 doses.…
Med Lett Drugs Ther. 2018 Jan 29; 60(1539):17-8
The FDA has approved a two-dose hepatitis B virus (HBV) vaccine ( Heplisav-B – Dynavax) for use in adults ≥18 years old. The three other HBV vaccines marketed in the US are usually administered in 3 doses. Engerix-B and Recombivax HB are licensed for use in persons of all ages. A combination hepatitis A/B vaccine (Twinrix) contains the same hepatitis B component as Engerix-B and is licensed for use only in adults.
The FDA has approved an adjuvanted, recombinant varicella zoster virus (VZV) vaccine ( Shingrix – GSK) for prevention of herpes zoster (shingles) in adults ≥50 years old. Shingrix is the second herpes…
Med Lett Drugs Ther. 2017 Dec 4; 59(1535):195-6
The FDA has approved an adjuvanted, recombinant varicella zoster virus (VZV) vaccine ( Shingrix – GSK) for prevention of herpes zoster (shingles) in adults ≥50 years old. Shingrix is the second herpes zoster vaccine to be approved in the US; Zostavax , a live-attenuated VZV vaccine approved for the same indication, has been available since 2006.
The 2017 adult immunization schedule approved by the CDC's Advisory Committee on Immunization Practices (ACIP) includes some new or revised recommendations. 1 The complete schedule is available on the CDC's…
Med Lett Drugs Ther. 2017 Apr 24; 59(1519):70
The 2017 adult immunization schedule approved by the CDC's Advisory Committee on Immunization Practices (ACIP) includes some new or revised recommendations. 1 The complete schedule is available on the CDC's website ( www.cdc.gov/vaccines/schedule ). New recommendations for use of influenza vaccine during the 2016-2017 season were included in a previous issue of The Medical Letter . 2 Updated recommendations for other vaccines are summarized below. Recommendations for routine use of vaccines in adults were reviewed in an earlier issue. 3 DK Kim et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older – United States, 2017. MMWR Morb Mortal Wkly Rep 2017; 66:136. Influenza vaccine for 2016-2017. Med Lett Drugs Ther 2016; 58:127. Adult immunization. Treat Guidel Med Lett 2014; 12:39. Gardasil 9 – a broader HPV vaccine. Med Lett Drugs Ther 2015; 57:47. Trumenba: a serogroup B meningococcal vaccine. Med Lett Drugs Ther 2015; 57:5. Bexsero – a second serogroup B meningococcal vaccine. Med Lett Drugs Ther 2015; 57:158. Download complete U.S. English article
The FDA has approved Vaxchora (PaxVax), a single-dose, oral, live-attenuated cholera vaccine, to protect against disease caused by Vibrio cholerae serogroup O1 in adults 18-64 years old traveling to…
Med Lett Drugs Ther. 2016 Aug 29; 58(1502):113-4
The FDA has approved Vaxchora (PaxVax), a single-dose, oral, live-attenuated cholera vaccine, to protect against disease caused by Vibrio cholerae serogroup O1 in adults 18-64 years old traveling to cholera-affected areas. Vaxchora is the only cholera vaccine available in the US. A whole-cell killed injectable vaccine was previously approved, but is no longer available in the US.
The FDA has approved Fluad (Seqirus), an adjuvanted trivalent seasonal influenza vaccine, for immunization of adults ≥65 years old. It will become available later this year for use during the 2016-2017…
Med Lett Drugs Ther. 2016 Jan 18; 58(1486):8
The FDA has approved Fluad (Seqirus), an adjuvanted trivalent seasonal influenza vaccine, for immunization of adults ≥65 years old. It will become available later this year for use during the 2016-2017 influenza season. Fluad is the second influenza vaccine to be approved in the US specifically for older adults; Fluzone High-Dose was the first. Fluad has been available in other countries for many years.
The FDA has approved Bexsero (Novartis/GSK), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B. It is the second serogroup B meningococcal vaccine to…
Med Lett Drugs Ther. 2015 Nov 23; 57(1482):158-9
The FDA has approved Bexsero (Novartis/GSK), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B. It is the second serogroup B meningococcal vaccine to be approved in the US; Trumenba was the first. Both vaccines are approved for use in persons 10-25 years old. Bexsero is approved in Europe, Canada, and Australia for use in children as young as 2 months old.
In 2014, the US Advisory Committee on Immunization Practices (ACIP) recommended that all adults 65 years old and older being vaccinated against pneumococcus for the first time receive the pneumococcal…
Med Lett Drugs Ther. 2015 Oct 12; 57(1479):144
In 2014, the US Advisory Committee on Immunization Practices (ACIP) recommended that all adults 65 years old and older being vaccinated against pneumococcus for the first time receive the pneumococcal conjugate vaccine (PCV13) followed 6 to 12 months later by the pneumococcal polysaccharide vaccine (PPSV23) (Med Lett Drugs Ther 2014; 56:102) . In June 2015, the ACIP changed the recommended interval between the two vaccines to >1 year for immunocompetent adults ≥65 years old (MMWR Morbid Mortal Wkly Rep 2015; 674:944). Separating the vaccines by a year or more may improve the immune response to the serotypes in both vaccines. If a dose of PPSV23 is given earlier than the recommended interval, it does not need to be repeated. Download complete U.S. English article
The FDA has now approved a recombinant, 9-valent, human papillomavirus (HPV) vaccine ( Gardasil 9 – Merck) for use in girls and women 9-26 years old and boys 9-15 years old. The new vaccine is indicated to…
Med Lett Drugs Ther. 2015 Mar 30; 57(1465):47-8
The FDA has now approved a recombinant, 9-valent, human papillomavirus (HPV) vaccine ( Gardasil 9 – Merck) for use in girls and women 9-26 years old and boys 9-15 years old. The new vaccine is indicated to prevent diseases associated with infection with HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, which include genital warts and cervical, vulvar, vaginal, and anal precancerous lesions and cancer. Two recombinant HPV vaccines are already available in the US: Gardasil prevents disease associated with HPV types 6, 11, 16, and 18, and Cervarix prevents disease associated with HPV types 16 and 18.
The FDA has approved peramivir ( Rapivab – BioCryst), an IV neuraminidase inhibitor administered as a single dose, for treatment of acute uncomplicated influenza in patients ≥18 years old who have had…
Med Lett Drugs Ther. 2015 Feb 2; 57(1461):17-9
The FDA has approved peramivir ( Rapivab – BioCryst), an IV neuraminidase inhibitor administered as a single dose, for treatment of acute uncomplicated influenza in patients ≥18 years old who have had symptoms for no more than 2 days. Peramivir was available temporarily in the US during the 2009-2010 influenza season under an emergency use authorization for treatment of hospitalized patients. It has been available in some Asian countries since 2010. Peramivir is the third neuraminidase inhibitor to be approved in the US. Oseltamivir (Tamiflu) , which is taken orally, and zanamivir (Relenza) , which is inhaled, are approved for prophylaxis and treatment of influenza in children and adults.
The FDA has approved Trumenba (Pfizer), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B, for use in adolescents and young adults 10-25 years old.
Med Lett Drugs Ther. 2015 Jan 5; 57(1459):5-6
The FDA has approved Trumenba (Pfizer), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B, for use in adolescents and young adults 10-25 years old.
The CDC has announced that the most common influenza viruses circulating now are influenza A H3N2, which tend to cause more severe disease, and that about half of these viruses are antigenically different from…
Med Lett Drugs Ther. 2015 Jan 5; 57(1459):1
The CDC has announced that the most common influenza viruses circulating now are influenza A H3N2, which tend to cause more severe disease, and that about half of these viruses are antigenically different from the H3N2 strain in this year’s flu vaccine. 1 Vaccination may still have a protective effect, even against drifted variants, and patients who have not received this year’s vaccine 2 should be encouraged to do so. Prompt treatment of confirmed or suspected influenza illness with antiviral drugs is recommended for hospitalized patients, for those with severe, complicated, or progressive illness, and for persons at high risk of complications: children <2 years old, adults ≥65 years old, women who are pregnant or ≤2 weeks postpartum, persons <19 years old receiving long-term aspirin therapy, morbidly obese patients (BMI ≥40), persons of American Indian/Alaskan Native heritage, residents of nursing homes or chronic-care facilities, and patients who are immunosuppressed or have chronic diseases such as asthma, diabetes, or heart, lung, or kidney disease. The neuraminidase inhibitors oseltamivir (Tamiflu) , which is taken orally, and zanamivir (Relenza) , which is inhaled, taken within 48 hours after the onset of illness can decrease the duration of fever and symptoms in uncomplicated influenza and may reduce the incidence of pneumonia and death in high-risk patients. 3 All of the influenza viruses tested to date for resistance to neuraminidase inhibitors this season have been susceptible to both oseltamivir and zanamivir. 1 CDC health advisory regarding the potential for circulation of drifted influenza A (H3N2) viruses. Available at http://emergency.cdc.gov. Accessed December 18, 2014. Influenza vaccine for 2014-2015. Med Lett Drugs Ther 2014; 56:97. Antiviral drugs for seasonal influenza 2014-2015. Med Lett Drugs Ther 2014; 56:121. Download complete U.S. English article
For initial treatment of rheumatoid arthritis, most expert clinicians prescribe a disease-modifying antirheumatic drug (DMARD) and add a nonsteroidal anti-inflammatory drug (NSAID) or a corticosteroid to…
Med Lett Drugs Ther. 2014 Dec 22; 56(1458):127-32
For initial treatment of rheumatoid arthritis, most expert clinicians prescribe a disease-modifying antirheumatic drug (DMARD) and add a nonsteroidal anti-inflammatory drug (NSAID) or a corticosteroid to control symptoms. Methotrexate is generally the DMARD of choice... DMARDs Disease-modifying antirheumatic drugs (DMARDs) are used early in the treatment of rheumatoid arthritis (RA) to achieve clinical remission, prevent irreversible damage to joints, and minimize toxicity associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. DMARDs generally do not have an immediate analgesic effect, but over time can control symptoms and have been shown to delay and possibly stop progression of the disease. Methotrexate ( Rheumatrex , and others) is generally the first DMARD prescribed; it can be used to treat mild, moderate, or severe RA. For mild disease, some clinicians prefer to start with hydroxychloroquine ( Plaquenil , and generics) and/or sulfasalazine ( Azulfidine , and others).
Patients planning to travel to other countries should be up to date on routine immunizations and, depending on their destination, duration of travel, and planned activities, may also need to receive certain…
Med Lett Drugs Ther. 2014 Nov 24; 56(1456):115-20
Patients planning to travel to other countries should be up to date on routine immunizations and, depending on their destination, duration of travel, and planned activities, may also need to receive certain travel-specific vaccines. Common travel vaccines are listed in Table 2. More detailed advice for travelers is available from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/travel. Guidelines for routine adult immunization are discussed in a separate issue.
The US Advisory Committee on Immunization Practices (ACIP) now recommends routine immunization with 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13 ), in addition to the 23-valent pneumococcal…
Med Lett Drugs Ther. 2014 Oct 13; 56(1453):102
The US Advisory Committee on Immunization Practices (ACIP) now recommends routine immunization with 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13 ), in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23 ), for all adults ≥65 years old. 1 An unpublished, randomized, double-blind trial (CAPiTA) in about 85,000 adults ≥65 years old found that vaccination with PCV13 reduced first episodes of vaccine-type community-acquired pneumonia and invasive pneumococcal disease by 46% and 75%, respectively, compared to placebo. 2 Adults ≥65 years old who previously received ≥1 dose of PPSV23 should also receive PCV13, but at least one year after the last dose of PPSV23. For those receiving the pneumococcal vaccine for the first time, PCV13 should be given first, followed 6-12 months later by PPSV23. PCV13 can be given at the same time as an inactivated influenza vaccine. Currently, Medicare only pays for one lifetime dose of a pneumococcal vaccine for healthy patients. S Tomczyk et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63:822. M Bonten et al. Community acquired pneumonia immunisation trial in adults (CAPITA). Abstract #O-015. International Symposium on Pneumococci and Pneumococcal Diseases 2014. Available at: http://isppd.meetingxpert.net. Accessed October 2, 2014. Download complete U.S. English article
Wild poliovirus has circulated during the previous 12 months in Cameroon, Equatorial Guinea, Ethiopia, Iraq, Israel (also the West Bank and Gaza), Somalia, and Syria, as well as in those countries where polio…
Med Lett Drugs Ther. 2014 Sep 1; 56(1450):84
Wild poliovirus has circulated during the previous 12 months in Cameroon, Equatorial Guinea, Ethiopia, Iraq, Israel (also the West Bank and Gaza), Somalia, and Syria, as well as in those countries where polio is still endemic (Afghanistan, Nigeria, and Pakistan). The World Health Organization (WHO) has declared a public health emergency related to the possible spread of polio from affected countries. In response, the Centers for Disease Control and Prevention (CDC) has issued interim guidance for US residents planning travel to and from these countries. Vaccine Recommendations – All travelers to countries with wild poliovirus circulation during the last 12 months should have completed a primary series of inactivated polio vaccine (IPV; IPOL – Sanofi-Pasteur) before departure. Adults who have not previously been immunized against polio should receive a 3-dose primary series of IPV (2 doses 4-8 weeks apart; third dose 6-12 months after the second). If protection is needed sooner, 2 or 3 doses ≥4 weeks apart can be given; if <4 weeks are available before protection is needed, a single dose is recommended. Adults who previously completed a primary series and have never had a booster should receive a single booster dose of IPV. Previously unimmunized children should receive a 4-dose primary series of IPV. The first dose can be given at age ≥6 weeks; the minimum interval is 4 weeks between doses 1 and 2 and 2 and 3, and is 6 months between doses 3 and 4. A child who received 4 doses before age 4 should be given a fifth dose. 1 Interim Guidance – Travelers planning to stay for >4 weeks in a polio-infected country may be required to present proof of polio vaccination when departing that country. The CDC is now recommending that all polio vaccine administration for travelers be documented on an International Certificate of Vaccination or Prophylaxis ("yellow card"). Children and adults who will be in a polio-infected country for >4 weeks, and whose last dose of polio vaccine was administered >12 months before the date they will be leaving that country should receive an additional dose of IPV before leaving the US. Those who plan to reside in a polio-infected country for >12 months may be required to receive a dose of the polio vaccine that is available in that country (either IPV or oral polio vaccine) between 4 weeks and 12 months before their departure from the polio-infected country. 2 Advice for Travelers. Treat Guidel Med Lett 2012; 10:45. GS Wallace et al. Interim CDC guidance for polio vaccination for travel to and from countries affected by wild poliovirus. MMWR Morb Mortal Wkly Rep 2014; 63:591. Download complete U.S. English article
Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately. Eight vaccines are currently recommended by the US Advisory Committee on Immunization…
Treat Guidel Med Lett. 2014 Jun; 12(142):39-48
Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately. Eight vaccines are currently recommended by the US Advisory Committee on Immunization Practices (ACIP) for routine use in adults at various ages...
An outbreak of mumps has occurred among students at Fordham University in New York. All of those who developed mumps had been vaccinated against the disease.
Med Lett Drugs Ther. 2014 Mar 17; 56(1438):21
An outbreak of mumps has occurred among students at Fordham University in New York. All of those who developed mumps had been vaccinated against the disease.
An outbreak (8 cases to date) of meningococcal disease at Princeton University caused by Neisseria meningitidis serogroup B has led the FDA and CDC to permit importation and investigational use (at Princeton…
Med Lett Drugs Ther. 2013 Dec 9; 55(1431):97
An outbreak (8 cases to date) of meningococcal disease at Princeton University caused by Neisseria meningitidis serogroup B has led the FDA and CDC to permit importation and investigational use (at Princeton University only) of a meningococcus B vaccine (4CMenB; Bexsero – Novartis) that has not been approved in the US. Bexsero has been approved for use in the European Union and in Australia. THE VACCINE — Until recently, no serogroup B vaccine was widely available because the polysaccharide capsule of the B serogroup, unlike those of the other main meningococcal serogroups (A, C, Y, and W-135), is only weakly immunogenic. The 4CMenB vaccine contains 3 protein antigens identified in the N. meningitidis serogroup B genome and membrane components from a New Zealand outbreak strain. The vaccine has been tested in more than 8000 adults and children, has proved to be immunogenic, and appears to be safe. 1 Its efficacy has not been established clinically, but laboratory testing, according to the CDC, has found that the vaccine should be protective against the strain causing the Princeton University outbreak. Bactericidal antibody levels develop about 2 weeks after one dose of the vaccine; a second dose is needed 1-6 months after the first to maintain protection. CHEMOPROPHYLAXIS — Close contacts of patients with invasive meningococcal disease (e.g., same household, roommates, boyfriend or girlfriend) should receive antimicrobial chemoprophylaxis. Antimicrobial drugs can prevent secondary cases and eradicate the organism from the nasopharynx of healthy carriers. The susceptibility of serogroup B meningococci to antimicrobial agents is the same as that of other meningococcal serogroups. Regimens recommended by the CDC’s Advisory Committee on Immunization Practices are: oral rifampin 600 mg (10 mg/kg for children) q12h for 2 days; oral ciprofloxacin 500 mg once (not recommended for children); or a single IM injection of ceftriaxone 250 mg (125 mg for children). 2 CONCLUSION — The new vaccine against serogroup B meningococcal disease, which is investigational in the US, appears to be immunogenic and safe. For immediate protection after close contact with an infected patient, antimicrobial prophylaxis is recommended. 1. NJ Carter. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero®): a review of its use in primary and booster vaccination. BioDrugs 2013; 27:263. 2. AC Cohn et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62(RR-2):1. Download complete U.S. English article
Rates of meningococcal disease are highest in infancy, but until recently no meningococcal vaccine was approved for use in this age group. MenHibrix (GSK), a new conjugate vaccine that protects against…
Med Lett Drugs Ther. 2013 Nov 11; 55(1429):92
Rates of meningococcal disease are highest in infancy, but until recently no meningococcal vaccine was approved for use in this age group. MenHibrix (GSK), a new conjugate vaccine that protects against Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b (Hib), has been approved by the FDA for use in infants ≥6 weeks old and Menveo , a meningococcal vaccine already approved for patients ≥2 years old that protects against serogroups A, C, Y, and W-135, is now approved for use in infants ≥2 months old. SEROGROUPS — Five major serogroups of N. meningitidis , A, B, C, Y, and W-135, cause most of the reported cases of invasive meningococcal disease. Serogroup A is the leading cause of epidemic meningitis worldwide, especially in the meningitis belt of sub-Saharan Africa, but it is rare in the US. Serogroup B causes about 60% of all meningitis cases in infants and, together with serogroups C and Y, accounts for most of the endemic disease in the US. Serogroup W-135 has caused outbreaks worldwide, particularly among pilgrims to Mecca during the Hajj and their close contacts on arriving home. Serogroup B remains the only major serogroup for which no vaccine is available in the US. A meningococcal B vaccine ( Bexsero – Novartis) is licensed in Europe and Australia for patients ≥2 months old. IMMUNOLOGIC STUDIES — FDA approval of both MenHibrix and Menveo (for this age group) was based on immunologic studies in infants who received the vaccines at 2, 4, 6, and 12 months. Both vaccines produced protective antibody responses in almost all vaccinated infants. With MenHibrix , antibody levels against Hib were non-inferior to those with 2 standard monovalent Hib vaccines. 1 RECOMMENDATIONS FOR USE — The CDC’s Advisory Committee on Immunization Practices (ACIP) does not recommend routine vaccination against meningococcal disease for infants. It does recommend use of either MenHibrix or Menveo for infants who are at increased risk of meningococcal disease because of persistent complement deficiencies, functional or anatomic asplenia, or exposure to a community outbreak of disease caused by one of the serogroups in the vaccine. 2 Menveo is also recommended for infants traveling with their families to the Hajj or to the meningitis belt of sub-Saharan Africa. Both vaccines can be given on a 4-dose schedule at 2, 4, 6, and 12 months, but the first dose of MenHibrix can be administered as early as 6 weeks and the last dose as late as 18 months. 1. KA Bryant et al. Immunogenicity and safety of H. influenzae type b-N meningitidis C/Y conjugate vaccine in infants. Pediatrics 2011; 127:e1375. 2. AC Cohn et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62(RR-2):1. Download complete U.S. English article
Annual vaccination against influenza A and B viruses has been shown to decrease influenza illness and its complications. Several new vaccines are available for the current season.
Med Lett Drugs Ther. 2013 Sep 16; 55(1425):73-5
Annual vaccination against influenza A and B viruses has been shown to decrease influenza illness and its complications. Several new vaccines are available for the current season.
Two new trivalent influenza vaccines, Flucelvax (Novartis) and Flublok (Protein Sciences), will soon be available for prevention of seasonal influenza in adults ≥18 years old (Flucelvax) and 18-49 years old…
Med Lett Drugs Ther. 2013 Feb 4; 55(1409):12
Two new trivalent influenza vaccines, Flucelvax (Novartis) and Flublok (Protein Sciences), will soon be available for prevention of seasonal influenza in adults ≥18 years old (Flucelvax) and 18-49 years old (Flublok) . Unlike other available influenza vaccines, neither vaccine is produced in eggs, removing any concern regarding use in egg-allergic patients. Avoiding the use of eggs should allow for faster production of these 2 new vaccines, which could be especially beneficial during a pandemic. Flucelvax is prepared in a similar manner to other influenza vaccines, but the influenza virus is grown in canine kidney cell culture instead of chicken eggs. In an unpublished study summarized in the package insert comparing Flucelvax with placebo in more than 11,000 patients during the 2007-2008 season, the new vaccine was effective in preventing about 84% of cases of influenza due to matching strains and was about 70% effective when non-matching strains were included. Flublok is produced without use of influenza virus or chicken eggs; a gene that encodes for hemagglutinin antigen (HA) is introduced into baculovirus, a virus that infects insect cells, and the replicating baculovirus produces large amounts of HA. In a study in about 4,600 adults conducted during one influenza season, Flublok was about 45% effective compared to placebo in preventing culture-confirmed influenza despite a significant antigenic mismatch between the vaccine and circulating viruses (96% of circulating strains did not match the vaccine). It was 75% effective in preventing illness caused by matching strains. 1 Both Flublok and Flucelvax provide protection against the same strains as the other vaccines available for the 2012-2013 influenza season. 2 1. JJ Treanor et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29:7733. 2. Influenza vaccine 2012-2013. Med Lett Drugs Ther 2012; 54:77. Download complete U.S. English article
The US Advisory Committee on Immunization Practices (ACIP) has recommended that adults with immunocompromising conditions receive the 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13 ), even if they…
Med Lett Drugs Ther. 2012 Oct 29; 54(1402):87-8
The US Advisory Committee on Immunization Practices (ACIP) has recommended that adults with immunocompromising conditions receive the 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13 ), even if they have already received the older 23-valent unconjugated vaccine (PPSV23; Pneumovax 23 ). Prevnar 13 , initially approved by the FDA for use in infants and young children, has been licensed since December 2011 for adults ≥50 years old.
Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza and has been shown to decrease influenza illness and its complications. A new vaccine is available for…
Med Lett Drugs Ther. 2012 Oct 1; 54(1400):77-8
Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza and has been shown to decrease influenza illness and its complications. A new vaccine is available for the current season. Chemoprophylaxis and treatment of influenza was discussed in an earlier issue.
The CDC has reported that many states are experiencing a higher-than-usual incidence of pertussis this year. The highest incidence has been in infants, but the disease has also occurred in older children,…
Med Lett Drugs Ther. 2012 Sep 17; 54(1399):73-4
The CDC has reported that many states are experiencing a higher-than-usual incidence of pertussis this year. The highest incidence has been in infants, but the disease has also occurred in older children, adolescents, and adults. Thirteen pertussis-related deaths were reported through August 24; the majority of these were in infants <3 months old.
Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to achieve clinical remission, prevent irreversible damage to joints, and minimize toxicity…
Treat Guidel Med Lett. 2012 May; 10(117):37-44
Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to achieve clinical remission, prevent irreversible damage to joints, and minimize toxicity associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. DMARDs (Table 1) generally do not have an immediate analgesic effect, but over time can control symptoms and have been shown to delay and possibly stop progression of the disease. NSAIDs have immediate analgesic and antiinflammatory effects, but may not affect the disease process. Oral corticosteroids can relieve joint symptoms and control systemic manifestations, but their chronic use can cause many complications. Judicious use of intra-articular corticosteroids can rapidly decrease inflammation in acute joints with few, if any, adverse effects.
Live-attenuated vaccines are generally contraindicated during pregnancy; inactivated vaccines can be given if indicated. A more detailed review of routine immunizations for adults will be available in the…
Med Lett Drugs Ther. 2011 Nov 28; 53(1378):94-6
Live-attenuated vaccines are generally contraindicated during pregnancy; inactivated vaccines can be given if indicated. A more detailed review of routine immunizations for adults will be available in the December issue of Treatment Guidelines from The Medical Letter .
Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza and has been shown to decrease influenza illness and complications. For the current season, a new…
Med Lett Drugs Ther. 2011 Oct 17; 53(1375):81-3
Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza and has been shown to decrease influenza illness and complications. For the current season, a new inactivated intradermal vaccine (Fluzone Intradermal) has been FDA-approved for use in adults 18-64 years old. An upcoming issue will review chemoprophylaxis and treatment of influenza.
Evidence of waning immunity by 5 years post-vaccination has led the US Advisory Committee on Immunization Practices (ACIP) to recommend, in addition to a primary dose of meningococcal conjugate vaccine at 11…
Med Lett Drugs Ther. 2011 May 16; 53(1364):37
Evidence of waning immunity by 5 years post-vaccination has led the US Advisory Committee on Immunization Practices (ACIP) to recommend, in addition to a primary dose of meningococcal conjugate vaccine at 11 or 12 years of age, a booster dose at age 16. Adolescents who receive a first dose of the vaccine at age 13-15 should receive a booster dose at 16-18 (before college). Those who receive their first dose at ≥16 years of age do not need a booster dose. Routine vaccination of healthy persons who are not at increased risk for exposure to Neisseria meningitidis is not recommended after age 21. 1 1. CDC. Updated recommendations for use of meningococcal conjugate vaccines — Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011; 60:72. Download U.S. English
The FDA has approved a new indication for prevention of anal cancer and anal intraepithelial neoplasia in both sexes for the human papillomavirus (HPV) vaccine Gardasil (Merck). This vaccine is already…
Med Lett Drugs Ther. 2011 Mar 7; 53(1359):20
The FDA has approved a new indication for prevention of anal cancer and anal intraepithelial neoplasia in both sexes for the human papillomavirus (HPV) vaccine Gardasil (Merck). This vaccine is already FDA-approved for prevention of cervical cancer and genital warts in females 9-26 years old and for prevention of genital warts in males 9-26 years old. HPV types 6 and 11 cause about 90% of genital warts. Types 16 and 18 cause more than 70% of cervical cancer and about 80% of anal cancer. 1 Gardasil is highly effective in preventing infection with HPV types 6, 11, 16 and 18 in both males and females. 2,3 (A second HPV vaccine, Cervarix , is also effective in preventing infection with types 16 and 18, but has no activity against types 6 and 11; it has not been approved for any indication in males. 4 ) Since 40% of women become infected with HPV within 16 months after initiation of sexual activity and neither vaccine prevents cancer if it is given after infection, vaccination against HPV is now recommended routinely for girls 11-12 years old. Routine vaccination of boys with Gardasil would benefit unvaccinated girls as well as the boys themselves. 1. H De Vuyst et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124:1626. 2. A human papillomavirus vaccine. Med Lett Drugs Ther 2006; 48:65. 3. AR Giuliano et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011; 364:401. < 4. Cervarix – A second HPV vaccine. Med Lett Drugs Ther 2010; 52:37. Download U.S. English
The FDA has licensed a 13-valent conjugate pneumococcal vaccine (PCV13; Prevnar 13 – Pfizer) for the prevention of invasive pneumococcal disease (IPD) in infants and children <6 years old. It replaces…
Med Lett Drugs Ther. 2010 Aug 23; 52(1345):67-8
The FDA has licensed a 13-valent conjugate pneumococcal vaccine (PCV13; Prevnar 13 – Pfizer) for the prevention of invasive pneumococcal disease (IPD) in infants and children <6 years old. It replaces Prevnar (PCV7). An unconjugated 23-valent polysaccharide vaccine (PPSV23; Pneumovax 23 – Merck) is FDA-approved for use in adults.
The 2006 Medical Letter article on the then-new varicella-zoster vaccine concluded that Zostavax appears to be safe and effective in protecting patients ≥60 years old against herpes zoster and postherpetic…
Med Lett Drugs Ther. 2010 May 31; 52(1339):41
The 2006 Medical Letter article on the then-new varicella-zoster vaccine concluded that Zostavax appears to be safe and effective in protecting patients ≥60 years old against herpes zoster and postherpetic neuralgia, especially in reducing the severity and duration of the disease. 1 Some new information has recently become available. CLINICAL STUDIES — A Veterans Administration randomized, double-blind trial enrolled more than 38,000 patients ≥60 years old and followed them for a mean of 3.4 years after administration of Zostavax or placebo. Since the efficacy of the vaccine had been demonstrated previously (51% in preventing zoster and 67% in preventing postherpetic neuralgia), the objective of this study was to examine its safety. Transient varicella-like rash occurred at the inoculation site in 0.11% of vaccine recipients and in 0.04% of patients who received a placebo injection. Erythema, swelling, pain and tenderness at the injection site were more frequent and more severe with the vaccine than with placebo. There were no other significant differences. Serious adverse events occurred in 1.4% of patients in each group. 2 USE — Despite its efficacy and the frequency and morbidity of herpes zoster, this vaccine is hardly used. One study in 2007 found that only 2% of patients ≥60 years old had received it. 3 A 2008 survey found that 7% of potential recipients had been vaccinated. 4 A study of the reasons for such sparse usage concluded that the expense ($194 wholesale), the need for a freezer to store the vaccine (a vaccine that can be kept in a refrigerator is available in Europe), and reimbursement through Medicare Part D, which generally provides pharmacy benefits, rather than Part B, which physicians are more familiar with, were contributing factors. 5 CONCLUSION — The efficacy of the herpes zoster vaccine (Zostavax) was well established before the FDA approved it in 2006. Several years’ use has now provided more data supporting the safety of the vaccine. It deserves wider use. 1. Herpes zoster vaccine (Zostavax). Med Lett Drugs Ther 2006; 48:73. 2. MS Simberkoff et al. Safety of herpes zoster vaccine in the shingles prevention study. Ann Intern Med 2010; 152:545. 3. PJ Lu et al. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine 2009; 27:882. 4. JS Schiller and GL Euler. Vaccination coverage estimates from the National Health Interview Survey: United States, 2008. Atlanta: Centers for Disease Control and Prevention 2009. Accessed at www.cdc.gov/nchs/data/hestat/vaccine_coverage/vaccine_coverage.pdf on 12 May 2010. 5. LP Hurley et al. Barriers to the use of herpes zoster vaccine. Ann Intern Med 2010; 152:555. Download: U.S. English
The FDA has approved a recombinant human papillomavirus (HPV) vaccine ( Cervarix – GlaxoSmithKline) for use in girls and women 10-25 years old to prevent infection with HPV types 16 and 18, which have been…
Med Lett Drugs Ther. 2010 May 17; 52(1338):37
The FDA has approved a recombinant human papillomavirus (HPV) vaccine ( Cervarix – GlaxoSmithKline) for use in girls and women 10-25 years old to prevent infection with HPV types 16 and 18, which have been associated with cervical cancer. A recombinant quadrivalent HPV vaccine ( Gardasil – Merck) already on the market in the US prevents infection with HPV types 6, 11, 16 and 18.
In 2007, Merck voluntarily recalled some lots of PedvaxHIB and Comvax , two Haemophilus influenzae type b (Hib) vaccines, and temporarily stopped their production because of possible contamination, resulting…
Med Lett Drugs Ther. 2009 Nov 2; 51(1324):88
In 2007, Merck voluntarily recalled some lots of PedvaxHIB and Comvax , two Haemophilus influenzae type b (Hib) vaccines, and temporarily stopped their production because of possible contamination, resulting in a shortage during which pediatricians were urged to defer giving Hib booster doses (normally given at 12-15 months) to healthy children. Now the FDA has granted accelerated licensure of Hiberix (GlaxoSmithKline), a monovalent vaccine conjugated with tetanus toxoid that has been used in Europe since 1996, as a booster (final) dose of the Hib series in children 15 months-4 years old. Hiberix can also be given to children 12-15 months old as a scheduled booster dose. 1 1. Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine. MMWR Morb Mortal Wkly Rep 2009; 58:1008. Download: U.S. English
The FDA has licensed 4 new monovalent vaccines for prevention of respiratory illness caused by a new influenza A H1N1 virus that appears to be derived from a swine strain. The 5th vaccine should be licensed…
Med Lett Drugs Ther. 2009 Oct 5; 51(1322):77-8
The FDA has licensed 4 new monovalent vaccines for prevention of respiratory illness caused by a new influenza A H1N1 virus that appears to be derived from a swine strain. The 5th vaccine should be licensed soon. All of these vaccines are expected to become available in October. An intranasal formulation is expected in the first week of October.
Two separate influenza vaccines will be available this season: the usual seasonal trivalent vaccine and a monovalent vaccine (not yet licensed by the FDA) directed at the novel H1N1 virus currently causing…
Med Lett Drugs Ther. 2009 Sep 21; 51(1321):73-4
Two separate influenza vaccines will be available this season: the usual seasonal trivalent vaccine and a monovalent vaccine (not yet licensed by the FDA) directed at the novel H1N1 virus currently causing pandemic infection. The next issue of the Medical Letter will review the pandemic H1N1 vaccine.
The FDA has approved a new Japanese encephalitis vaccine ( Ixiaro - Intercell/Novartis). It will replace JEVax (Sanofi Pasteur), which has had tolerability and safety problems and is no longer being…
Med Lett Drugs Ther. 2009 Aug 24; 51(1319):66
The FDA has approved a new Japanese encephalitis vaccine ( Ixiaro - Intercell/Novartis). It will replace JEVax (Sanofi Pasteur), which has had tolerability and safety problems and is no longer being manufactured.
Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal…
Treat Guidel Med Lett. 2009 May; 7(81):37-46
Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.
Rotarix , an oral live-attenuated rotavirus vaccine, has been approved by the FDA for prevention of rotavirus gastroenteritis in infants and children. Rota-Shield was withdrawn from the market because of an…
Med Lett Drugs Ther. 2008 Aug 25; 50(1293):66-7
Rotarix , an oral live-attenuated rotavirus vaccine, has been approved by the FDA for prevention of rotavirus gastroenteritis in infants and children. Rota-Shield was withdrawn from the market because of an association with intussusception. RotaTeq , an oral live, human-bovine reassortant rotavirus vaccine, is recommended by the American Academy of Pediatrics as a routine immunization.
The CDC recently reported that fluoroquinoloneresistant strains of Neisseria meningitidis have been detected for the first time in the US in an area around the border of North Dakota and Minnesota (CDC. MMWR,…
Med Lett Drugs Ther. 2008 Apr 7; 50(1283):25
The CDC recently reported that fluoroquinoloneresistant strains of Neisseria meningitidis have been detected for the first time in the US in an area around the border of North Dakota and Minnesota (CDC. MMWR, Feb 22, 2008). These isolates were all serogroup B, for which meningococcal vaccines ( Med Lett Drugs Ther 2005; 47:29 ) do not offer protection. Since many laboratories do not test N. meningitidis for antimicrobial susceptibility, it is possible that such resistance is more widespread. A single oral dose of ciprofloxacin ( Cipro , and others) 500 mg has been used for prophylaxis after close contact with infected patients. Oral rifampin ( Rifadin , and others) 600 mg (10 mg/kg for children) q12h for 2 days, a single IM injection of ceftriaxone ( Rocephin , and others) 250 mg (125 mg for children), or a single oral dose of azithromycin ( Zithromax , and others) 500 mg (10 mg/kg for children) are reasonable alternatives. Download U.S. English
Medical Letter consultants have brought to our attention some confusion that has accompanied the release of Adacel , a combination of tetanus toxoid, diphtheria toxoid and acellular pertussis antigens (Tdap)…
Med Lett Drugs Ther. 2007 Jan 15; 49(1252):8
Medical Letter consultants have brought to our attention some confusion that has accompanied the release of Adacel , a combination of tetanus toxoid, diphtheria toxoid and acellular pertussis antigens (Tdap) recently approved for use as a booster in adolescents and adults 11-64 years old (Med Lett Drugs Ther 2006; 48:5) . Another Tdap vaccine, Boostrix , is approved for use in adolescents 10-18 years old. Some adults have inadvertently been immunized with Daptacel or Infanrix (DTaP), which are intended for active immunization of infants and children 6 weeks to 6 years old. Such mix-ups were reported by the Institute for Safe Medication Practices (www.ismp.org) in the August 24 and December 2006 issues of its newsletter. The problem with giving these pediatric vaccines to adults is that they contain more diphtheria and pertussis antigens than the adult vaccine, and adults may have untoward reactions to these higher antigen levels. One consultant who inadvertently gave the pediatric vaccine to 80 adults reports that a few developed fever to 102ºF, and several developed severe erythema and swelling at the injection site. In the absence of a comparative trial, whether these reactions were due to the higher antigen load can only be a matter of speculation. The reasons for the mix-ups, according to the Institute, include the similarities in the brand names and packaging of Adacel and Daptacel in addition to the similar component antigens in the 2 products (the components of Adacel are listed in a different order and are labeled as “reduced” diphtheria toxoid and acellular pertussis). The manufacturer of Adacel and Daptacel intends to make changes in the packaging and labeling to clarify the differences between the products. The inadvertent administration of Infanrix to adults was caused by an electronic order entry program’s failure to differentiate between the adult and pediatric vaccines. Download U.S. English
Since the publication of our article on influenza vaccine (October 9, 2006), a fourth inactivated vaccine ( FluLaval - GlaxoSmithKline) has been approved by the FDA for use in people ≥18 years old. It is…
Med Lett Drugs Ther. 2006 Oct 23; 48(1246):85
Since the publication of our article on influenza vaccine (October 9, 2006), a fourth inactivated vaccine ( FluLaval - GlaxoSmithKline) has been approved by the FDA for use in people ≥18 years old. It is sold in 5-mL multi-dose vials. Each 0.5-mL intramuscular dose contains 25 mcg of mercury.
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications.
Med Lett Drugs Ther. 2006 Oct 9; 48(1245):81-3
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications.
A live attenuated varicella-zoster vaccine ( Zostavax - Merck) has been approved by the FDA for prevention of herpes zoster (HZ; zoster; shingles) in persons ≥60 years old. Each dose of Zostavax contains…
Med Lett Drugs Ther. 2006 Sep 11; 48(1243):73-4
A live attenuated varicella-zoster vaccine ( Zostavax - Merck) has been approved by the FDA for prevention of herpes zoster (HZ; zoster; shingles) in persons ≥60 years old. Each dose of Zostavax contains about 14 times as much varicella-zoster virus (VZV) as Varivax , which has been used in the US since 1995 to vaccinate against varicella (chicken pox).
A recombinant quadrivalent human-papillomavirus-like particle vaccine, Gardasil (Merck), has been approved by the FDA for use in girls and women 9-26 years old to prevent diseases associated with infection…
Med Lett Drugs Ther. 2006 Aug 14; 48(1241):65-6
A recombinant quadrivalent human-papillomavirus-like particle vaccine, Gardasil (Merck), has been approved by the FDA for use in girls and women 9-26 years old to prevent diseases associated with infection with human papillomavirus (HPV) types 6, 11, 16, and 18, including genital warts, precancerous cervical, vaginal or vulvar lesions, and cervical cancer.
The FDA has recently approved RotaTeq (Merck), an oral live, human-bovine reassortant rotavirus vaccine, for use in infants to prevent rotavirus gastroenteritis, a frequent cause of severe diarrhea in infancy.
Med Lett Drugs Ther. 2006 Jul 31; 48(1240):61-2
The FDA has recently approved RotaTeq (Merck), an oral live, human-bovine reassortant rotavirus vaccine, for use in infants to prevent rotavirus gastroenteritis, a frequent cause of severe diarrhea in infancy.
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed…
Treat Guidel Med Lett. 2006 Jul; 4(47):47-54
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed here. Immunizations for travel were reviewed in a recent issue.
Patients planning to travel to other countries often ask physicians for information about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers…
Treat Guidel Med Lett. 2006 May; 4(45):25-34
Patients planning to travel to other countries often ask physicians for information about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for Disease Control and Prevention at 877-FYI-TRIP (877-394-8747) or www.cdc.gov/travel .
The FDA has licensed Adacel (Aventis Pasteur) and Boostrix (GlaxoSmithKline), two new combination vaccines that include tetanus toxoid, diphtheria toxoid and acellular pertussis antigens (Tdap), for use as a…
Med Lett Drugs Ther. 2006 Jan 16; 48(1226):5-6
The FDA has licensed Adacel (Aventis Pasteur) and Boostrix (GlaxoSmithKline), two new combination vaccines that include tetanus toxoid, diphtheria toxoid and acellular pertussis antigens (Tdap), for use as a booster in adolescents and adults. In the past, older children and adults were not re-immunized against pertussis because of concerns about reactions to the whole-cell vaccine previously used in younger children. The CDC Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) have recommended that either of the new Tdap vaccines replace routine tetanus-diphtheria (Td) boosters in adolescents 11-18 years old, and Adacel should replace Td boosters in adults 19-64 years old.
Antiviral prophylaxis is indicated for influenza exposures that occur before (or less than 2 weeks after) vaccination with inactivated vaccine, or in years when circulating strains differ from those included…
Med Lett Drugs Ther. 2005 Nov 21; 47(1222):93-5
Antiviral prophylaxis is indicated for influenza exposures that occur before (or less than 2 weeks after) vaccination with inactivated vaccine, or in years when circulating strains differ from those included in the vaccine. Antiviral drugs can also be used for treatment of patients who develop symptoms of influenza, regardless of vaccination status. Please see Update: Influenza Resistance to Amantadine and Rimantadine
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications. A future issue of The Medical Letter will review drug…
Med Lett Drugs Ther. 2005 Oct 24; 47(1220):85-7
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications. A future issue of The Medical Letter will review drug prophylaxis and treatment of influenza.
The FDA has approved a conjugated polysaccharide vaccine, Menactra (Sanofi-Pasteur), for protection against disease caused by Neisseria meningitidis in people 11-55 years old, and the manufacturer has applied…
Med Lett Drugs Ther. 2005 Apr 11; 47(1206):29-31
The FDA has approved a conjugated polysaccharide vaccine, Menactra (Sanofi-Pasteur), for protection against disease caused by Neisseria meningitidis in people 11-55 years old, and the manufacturer has applied for approval for use in children 2 to 10 years old. An unconjugated meningoccocal polysaccharide vaccine ( Menomune - Sanofi-Pasteur) has been licensed in the US since 1981.
Due to the unanticipated shortage in the US supply of inactivated influenza vaccine, many persons who normally would have received the vaccine will be unable to get it this year. Antiviral drugs can be used…
Med Lett Drugs Ther. 2004 Oct 25; 46(1194):85-7
Due to the unanticipated shortage in the US supply of inactivated influenza vaccine, many persons who normally would have received the vaccine will be unable to get it this year. Antiviral drugs can be used for prophylaxis of unvaccinated persons who are exposed to influenza, and for treatment of both vaccinated and unvaccinated patients who develop symptoms of the disease.
Last year influenza season began in October, peaked in December (both much earlier than usual), and was associated with severe disease, particularly in children. Much of the illness was due to a circulating…
Med Lett Drugs Ther. 2004 Oct 11; 46(1193):83-4
Last year influenza season began in October, peaked in December (both much earlier than usual), and was associated with severe disease, particularly in children. Much of the illness was due to a circulating influenza A H3N2 strain (Fujian type) that had drifted antigenically from the H3N2 strain in the vaccine. The vaccine for the 2004-05 influenza season includes A/Wyoming/3/2003 (H3N2), which is antigenically equivalent to the Fujian strain, A/New Caledonia/20/99 (H1N1), which is unchanged, and a new B strain, either B/Jiangsu/10/2003 or B/Jilin/20/2003, which are both antigenically equivalent to B/Shanghai/361/2002.
Addendum: FluMist Storage: The storage requirements for FluMist, the intranasal live-attenuated influenza vaccine (Medical Letter 2003; 45:65) have changed. New data have shown that frost-free freezers are…
Med Lett Drugs Ther. 2004 Feb 16; 46(1176):16
Addendum: FluMist Storage: The storage requirements for FluMist, the intranasal live-attenuated influenza vaccine (Medical Letter 2003; 45:65) have changed. New data have shown that frost-free freezers are appropriate for storage for at least 3 months, without need for a freezer-box insert.
Unlike the last few years there is no early-season shortage of influenza vaccine. Immunization programs for all recommended individuals can proceed. There are 2 new influenza vaccine formulations available…
Med Lett Drugs Ther. 2003 Sep 29; 45(1166):78-80
Unlike the last few years there is no early-season shortage of influenza vaccine. Immunization programs for all recommended individuals can proceed. There are 2 new influenza vaccine formulations available this year, FluMist , an intranasal vaccine and Fluzone , a pediatric formulation. Timing, indications, adverse effects, dosage and cost of the vaccines is discussed. The drugs that can be used for prophylaxis of influenza are also reviewed.
FluMist (MedImmune), the first live-attenuated and first intranasally administered influenza vaccine, has been approved by the FDA to prevent influenza in healthy people 5-49 years old. Given as a nasal spray,…
Med Lett Drugs Ther. 2003 Aug 19; 45(1163):65-6
FluMist (MedImmune), the first live-attenuated and first intranasally administered influenza vaccine, has been approved by the FDA to prevent influenza in healthy people 5-49 years old. Given as a nasal spray, it stimulates immunity by viral replication in the upper respiratory tract. This vaccine apparently will be advertised directly to the public as a "needle-free" alternative to intramuscular influenza vaccine.
A new pentavalent vaccine ( Pediarix - GlaxoSmithKline), licensed by the FDA for children 6 weeks to 7 years old, includes the antigens from vaccines already marketed against diphtheria, tetanus and pertussis…
Med Lett Drugs Ther. 2003 May 12; 45(1156):37-8
A new pentavalent vaccine ( Pediarix - GlaxoSmithKline), licensed by the FDA for children 6 weeks to 7 years old, includes the antigens from vaccines already marketed against diphtheria, tetanus and pertussis (Infanrix) and hepatitis B (Engerix-B) , and a new inactivated polio component.
The heptavalent pneumococcal conjugate vaccine ( Prevnar - Wyeth) previously approved by the FDA for prevention of invasive pneumococcal disease in infants and children ( Medical Letter 2000; 42:25 ) has now…
Med Lett Drugs Ther. 2003 Mar 31; 45(1153):27-8
The heptavalent pneumococcal conjugate vaccine ( Prevnar - Wyeth) previously approved by the FDA for prevention of invasive pneumococcal disease in infants and children ( Medical Letter 2000; 42:25 ) has now also been approved for prevention of otitis media. Infants and young children have higher antibody responses to the heptavalent conjugate vaccine (PCV7) than to the older 23-valent pneumococcal polysaccharide vaccine (PPV23) used in adults and older children (D Murray and C Jackson, Mil Med 2002; 167:671).
The single sentence on vaccination site care in our recent article on Smallpox Vaccination (Vol. 45, page 2) needs clarification. In the past, the vaccination site was generally left uncovered, but current…
Med Lett Drugs Ther. 2003 Jan 20; 45(1148):8
The single sentence on vaccination site care in our recent article on Smallpox Vaccination (Vol. 45, page 2) needs clarification. In the past, the vaccination site was generally left uncovered, but current plans for Phase I call for it to be covered with both gauze to absorb liquid and a semipermeable membrane such as an Opsite dressing to prevent spread of the virus. This correction has been made in the web version of the issue.
Because of concerns about the possibility of bioterrorism involving smallpox, the US government is reinstituting smallpox vaccination ( https://www.cdc.gov/smallpox/; www.idsociety.org/bt/toc.htm ).…
Med Lett Drugs Ther. 2003 Jan 6; 45(1147):1-3
Because of concerns about the possibility of bioterrorism involving smallpox, the US government is reinstituting smallpox vaccination ( https://www.cdc.gov/smallpox/; www.idsociety.org/bt/toc.htm ). Vaccination is currently expected to proceed in three phases: the military and hospital smallpox response teams first, other health care workers, police and firefighters second, and the general public in the third phase. Except for the military, vaccination will be voluntary.
Influenza vaccine for the 2002-2003 season will include last year's A strains, A/New Caledonia/20/99 (H1N1)-like and A/Moscow/10/99 (H3N2)-like, and a new B strain, B/Hong-Kong/330/01-like (MMWR Morb Mortal…
Med Lett Drugs Ther. 2002 Sep 2; 44(1138):75-6
Influenza vaccine for the 2002-2003 season will include last year's A strains, A/New Caledonia/20/99 (H1N1)-like and A/Moscow/10/99 (H3N2)-like, and a new B strain, B/Hong-Kong/330/01-like (MMWR Morb Mortal Wkly Rep 2002; 51:503).
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the CDC at…
Med Lett Drugs Ther. 2002 Apr 15; 44(1128):33-8
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the CDC at 877-FYI-TRIP (877-394-8747) or www.cdc.gov/travel .
Superseded by Handbook of Antimicrobial Therapy The Medical Letter article on Drugs and Vaccines against Biological Weapons, published in the previous issue (October 15, 2001, page 87), included a brief…
Med Lett Drugs Ther. 2001 Oct 29; 43(1116):91-2
Superseded by Handbook of Antimicrobial Therapy The Medical Letter article on Drugs and Vaccines against Biological Weapons, published in the previous issue (October 15, 2001, page 87), included a brief discussion of post-exposure prophylaxis of inhalation anthrax. Recent events call for more detail.
The US Public Health Service Advisory Committee on Immunization Practices has recently published new recommendations for prevention and control of meningococcal disease in college students.
Med Lett Drugs Ther. 2000 Aug 7; 42(1084):69
The US Public Health Service Advisory Committee on Immunization Practices has recently published new recommendations for prevention and control of meningococcal disease in college students.
A new trivalent influenza vaccine for intramuscular use is available for the 1997-1998 influenza season (Morbid Mortal Weekly Rep, 46 RR-9, April 25, 1997). Antigens in the current vaccine are…
Med Lett Drugs Ther. 1997 Sep 12; 39(1009):85-6
A new trivalent influenza vaccine for intramuscular use is available for the 1997-1998 influenza season (Morbid Mortal Weekly Rep, 46 RR-9, April 25, 1997). Antigens in the current vaccine are A/johannesburg/82/96, antigenically equivalent to A/Bayern/07/95 (H1N1); A/Nanchang/933/95, antigenically equivalent to A/Wuhan/359/95 (H3N2); and B/Harbin/07/94, antigenically equivalent to B/Beijing/184/93. Only the H1N1 antigen is new this year. A highly publicized nasal spray flu vaccine still has not been approved by the FDA and will not be available in the USA for use in the current influenza season.
The Centers for Disease Control and Prevention is anticipating a delay, but not a shortage, of influenza vaccine for the 2001-2002 season. Last year manufacturing problems led to a substantial delay in vaccine…
Med Lett Drugs Ther. 1996 Sep 13; 38(983):86
The Centers for Disease Control and Prevention is anticipating a delay, but not a shortage, of influenza vaccine for the 2001-2002 season. Last year manufacturing problems led to a substantial delay in vaccine availability. This years delay is being attributed, in part, to the discontinuation of the Fluogen (King) brand of vaccine. The 2001-02 vaccine will include A/New Caledonia/20/99 (H1N1)-like, A/Moscow/10/99 (H3N2)-like, and B/Sichuan/379/99-like antigens (MMWR Morb Mortal Wkly Rep, 50 RR-4:5, April 30, 2001).
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the CDC at…
Med Lett Drugs Ther. 1996 Mar 1; 38(969):17-20
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the CDC at 877-FYI-TRIP (877-394-8747) or www.cdc.gov/travel.
A new trivalent influenza vaccine is available for the 1995-1996 influenza season. Influenza vaccine, made from inactivated virus grown in eggs, is recommended especially for elderly and high-risk patients,…
Med Lett Drugs Ther. 1995 Sep 1; 37(956):78
A new trivalent influenza vaccine is available for the 1995-1996 influenza season. Influenza vaccine, made from inactivated virus grown in eggs, is recommended especially for elderly and high-risk patients, their household contacts and health-care personnel who may come in contact with such patients (Morbid Mortal Weekly Rep, 44, RR-3, April 21, 1995). Antigens in the current vaccine are derived from A/Texas/36/91/ (H1N1), A/Johannesburg and B/Harbin antigens are new this year.
A live attenuated varicella vaccine ( Varivax - Merck) has been approved for marketing by the US Food and Drug Administration. The Oka/Merck strain used in the vaccine is attenuated by passage in human and…
Med Lett Drugs Ther. 1995 Jun 23; 37(951):55-7
A live attenuated varicella vaccine ( Varivax - Merck) has been approved for marketing by the US Food and Drug Administration. The Oka/Merck strain used in the vaccine is attenuated by passage in human and embryonic guinea pig cell cultures.
A vaccine to prevent hepatitis A ( Havrix - SmithKline Beecham), previously licensed in more than 40 countries, including Canada, is now available in the United States. A similar vaccine manufactured by Merck…
Med Lett Drugs Ther. 1995 Jun 9; 37(950):51-2
A vaccine to prevent hepatitis A ( Havrix - SmithKline Beecham), previously licensed in more than 40 countries, including Canada, is now available in the United States. A similar vaccine manufactured by Merck is investigational in the USA.
Tacrolimus ( Prograf - Fujisawa), previously called FK506 (Medical Letter, 33:94, 1991), has been approved by the US Food and Drug Administration for primary prevention of organ rejection in patients receiving…
Med Lett Drugs Ther. 1994 Sep 16; 36(931):82-3
Tacrolimus ( Prograf - Fujisawa), previously called FK506 (Medical Letter, 33:94, 1991), has been approved by the US Food and Drug Administration for primary prevention of organ rejection in patients receiving liver transplants. The drug has also been used as rescue therapy for organ graft rejection unresponsive to cyclosporine (Sandimmune) and other immunosuppressive drugs.
The number of immunizations recommended for infants and young children has increased in recent years with the addition of vaccines to prevent Haemophilus influenzae type b infection and hepatitis B (Medical…
Med Lett Drugs Ther. 1993 Nov 12; 35(909):104-5
The number of immunizations recommended for infants and young children has increased in recent years with the addition of vaccines to prevent Haemophilus influenzae type b infection and hepatitis B (Medical Letter, 33:5, 1991; 34:69, 1992). Now the US Food and Drug Administration has licensed a new vaccine for infants ( Tetramune - Lederle-Praxis) that combines a traditional diphtheria, tetanus, and pertussis vaccine (DTP; Tri-Immunol ) with a vaccine against Haemophilus influenzae type b ( HibTiter ).
Masoprocol cream 10% (meso-nordihydroguiaretic acid, Actinex - Reed and Carnrick) is now available in the USA for topical treatment of actinic keratoses.
Med Lett Drugs Ther. 1993 Oct 15; 35(907):97-8
Masoprocol cream 10% (meso-nordihydroguiaretic acid, Actinex - Reed and Carnrick) is now available in the USA for topical treatment of actinic keratoses.
A new trivalent influenza vaccine is available for the 1993-1994 influenza season. Vaccination may be even more important than usual this year because of the appearance late in last year's flu season of a new…
Med Lett Drugs Ther. 1993 Sep 17; 35(905):89-90
A new trivalent influenza vaccine is available for the 1993-1994 influenza season. Vaccination may be even more important than usual this year because of the appearance late in last year's flu season of a new antigenic variant, which was associated with an increase in deaths (Morbid Mortal Weekly Rep, 42:385, May 28, 1993). Influenza vaccine is recommended especially for the elderly and high-risk patients, their household contacts, and health-care personnel who may come in contact with such patients (Morbid Mortal Weekly Rep, 42,RR-6, May 14, 1993).
A new trivalent influenza vaccine is now available for the 1992-1993 influenza season (Morbid Mortal Weekly Rep, 41, RR-9:1, May 15, 1992). Vaccination is recommended especially for elderly and high-risk…
Med Lett Drugs Ther. 1992 Sep 18; 34(879):90
A new trivalent influenza vaccine is now available for the 1992-1993 influenza season (Morbid Mortal Weekly Rep, 41, RR-9:1, May 15, 1992). Vaccination is recommended especially for elderly and high-risk patients, their household contacts, and health-care personnel who may come in contact with such patients. Antigens in the current vaccine are derived from A/Texas/36/91 (H1N1), A/Beijing/353/89 (H3N2), and B/Panama/45/90. The A/Texas/36/91 (H1N1) strain is new this year.
The Immunization Practices Advisory Committee of the US Public Health Service now recommends immunizing all infants and some adolescents against hepatitis B and using a new diphtheria-tetanus-acellular…
Med Lett Drugs Ther. 1992 Jul 24; 34(875):69-71
The Immunization Practices Advisory Committee of the US Public Health Service now recommends immunizing all infants and some adolescents against hepatitis B and using a new diphtheria-tetanus-acellular pertussis vaccine (DTaP; ACEL-IMUNE - Lederle) for the fourth and fifth doses of DTP, usually given at 15 to 18 months of age and before school entry (Morbid Mortal Weekly Rep, 40 RR-13:1, November 22, 1991; Morbid Mortal Weekly Rep, 41 RR-1:1, Feb 7, 1992). The Committee on Infectious Diseases of the American Academy of Pediatrics has made similar recommendations but would extend hepatitis B immunization to all adolescents, if possible (Committee on Infectious Diseases, Pediatrics, 89:795, April 1992).
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. Legal requirements for entry and epidemiological conditions in…
Med Lett Drugs Ther. 1992 May 1; 34(869):41-4
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. Legal requirements for entry and epidemiological conditions in different countries vary from time to time, often unpredictably, but some reasonable recommendations can be made. More detailed information is available in Health Information for International Travel , published annually by the Centers for Disease Control (CDC), which can be obtained from the Superintendent of Documents, US Government Printing Office, Washington, DC 20402. Up-to-date automated information is available by telephone from the CDC (404-332-4559).
A new trivalent influenza vaccine is now available for the 1991-1992 influenza season (Morbid Mortal Weekly Rep, 40, RR-6:1, May 24, 1991). Vaccination is recommended especially for elderly and high-risk…
Med Lett Drugs Ther. 1991 Sep 6; 33(852):86
A new trivalent influenza vaccine is now available for the 1991-1992 influenza season (Morbid Mortal Weekly Rep, 40, RR-6:1, May 24, 1991). Vaccination is recommended especially for elderly and high-risk patients, their household contacts, and health-care personnel who may come in contact with such patients. Antigens in the current vaccine are derived from A/Taiwan/1/86 (H1N1), A/Beijing/353/89 (H3N2), and B/Panama/45/90 are new this year.
With the deployment of hundreds of thousands of troops in Saudi Arabia, health problems endemic to the Arabian Peninsula may be coming to the attention of physicians in the USA and other areas.
Med Lett Drugs Ther. 1991 Feb 22; 33(838):13-5
With the deployment of hundreds of thousands of troops in Saudi Arabia, health problems endemic to the Arabian Peninsula may be coming to the attention of physicians in the USA and other areas.
The US Food and Drug Administration (FDA) recently approved HibTITER (Lederle-Praxis) and PedvaxHIB (Merck), two new Haemophilus influenzae type b conjugate vaccines, for use in infants as part of their…
Med Lett Drugs Ther. 1991 Jan 25; 33(836):5-7
The US Food and Drug Administration (FDA) recently approved HibTITER (Lederle-Praxis) and PedvaxHIB (Merck), two new Haemophilus influenzae type b conjugate vaccines, for use in infants as part of their primary immunization schedule.
Human rabies continues to be rare in the USA, but animal rabies is becoming more common. An animal epizootic in the mid-Atlantic states, involving especially raccoons, has recently spread into the northeastern…
Med Lett Drugs Ther. 1990 Dec 28; 32(834):117-8
Human rabies continues to be rare in the USA, but animal rabies is becoming more common. An animal epizootic in the mid-Atlantic states, involving especially raccoons, has recently spread into the northeastern states.
A new trivalent influenza vaccine is now available for the 1990-1991 influenza season (Morbid Mortal Weekly Rep, 39, RR7:1, May 11, 1990). Vaccination is recommended especially for elderly and high-risk…
Med Lett Drugs Ther. 1990 Sep 7; 32(826):86
A new trivalent influenza vaccine is now available for the 1990-1991 influenza season (Morbid Mortal Weekly Rep, 39, RR7:1, May 11, 1990). Vaccination is recommended especially for elderly and high-risk patients, their household contacts, and health-care personnel who may come in contact with such patients. Antigens in the vaccine include A/Taiwan/1/86 (H1N1), A/Shanghai/16/89 (H3N2), and B/Yamagata/16/88 is new this year.
Six vaccines are recommended for routine use in adults living in the USA ( Guide for Adult Immunization , 2nd ed, Philadelphia:American College of Physicians, 1990). Immunization recommendations for travel…
Med Lett Drugs Ther. 1990 Jun 1; 32(819):54-6
Six vaccines are recommended for routine use in adults living in the USA ( Guide for Adult Immunization , 2nd ed, Philadelphia:American College of Physicians, 1990). Immunization recommendations for travel outside the USA were published in The Medical Letter, volume 32, page 33, April 6, 1990.
A new trivalent inactivated influenza vaccine is now available for the 1989-1990 influenza season (Morbid Mortal Weekly Rep, 38:297, May 5, 1989: Can Med Assoc J, 141:425, Spet 1, 1989). Antigens in this…
Med Lett Drugs Ther. 1989 Oct 20; 31(803):95-6
A new trivalent inactivated influenza vaccine is now available for the 1989-1990 influenza season (Morbid Mortal Weekly Rep, 38:297, May 5, 1989: Can Med Assoc J, 141:425, Spet 1, 1989). Antigens in this years's Vaccine are A/Taiwan/1/86 (H1N1), A/Shanghai/11/87 (H3N2), and B/Yamagata/16/88. The A/Shanghai and B/Yamagata are new strains this year. The vaccine is available in the USA as a split-virus (subvirion) or whole virus preparation from Squibb ( Fluzone ), as a split-virus preparation from parke-davis ( Fluogen ) and Wyeth-Ayerst ( Influenza Virus Vaccine , Trivalent ), and as a purified-surface-antigen formulations may be less likely to cause adverse reactions, especially in children; whole-virus vaccines may be slighltly more antigenic. Vaccine from previous years should not be used.
In the first six months of 1989, more than 7,000 cases of measles were reported to the US Centers for Disease Control (CDC), a sharp increase over previous years (Morbid Mortal Weekly Rep, 33:456, July 7,…
Med Lett Drugs Ther. 1989 Jul 28; 31(797):69-70
In the first six months of 1989, more than 7,000 cases of measles were reported to the US Centers for Disease Control (CDC), a sharp increase over previous years (Morbid Mortal Weekly Rep, 33:456, July 7, 1989). Many of these cases occurred in children and college students who had previously been vaccinated against the disease. Practitioners have asked, therefore, whether their previously immunized young patients should receive a second (or, in some cases, third) immunization against measles.
A new trivalent inactivated influenza vaccine is now available for the 1988-1989 influenza season (Morbid Mortal Weekly Rep, 37:357, June 17, 1988). Antigens in this year's vaccine are A/Taiwan/1/86 (H1N1),…
Med Lett Drugs Ther. 1988 Aug 26; 30(773):83-4
A new trivalent inactivated influenza vaccine is now available for the 1988-1989 influenza season (Morbid Mortal Weekly Rep, 37:357, June 17, 1988). Antigens in this year's vaccine are A/Taiwan/1/86 (H1N1), A/Sichuan/2/87 (H3N2), and B/Victoria/2/87. The A/Sichuan is a new strain that caused last year's large outbreak of the disease. The vaccine is available in the USA as a split-virus (Subvirion) or whole virus preparation from Squibb ( Fluzone ), and as a split-virus preparation from Parke-Davis ( Fluogen ) and Wyeth ( Influenza Virus Vaccine, Trivalent ). Split-virus vaccines may be slightly more antigenic. Vaccine from previous years should not be used.
Mupirocin ( Bactroban - Beecham), a topical antibiotic formerly called pseudomonic acid, was recently approved by the US Food and Drug Administration for treatment of impetigo. It will be sold as a 2% ointment…
Med Lett Drugs Ther. 1988 May 20; 30(766):55-6
Mupirocin ( Bactroban - Beecham), a topical antibiotic formerly called pseudomonic acid, was recently approved by the US Food and Drug Administration for treatment of impetigo. It will be sold as a 2% ointment available only by prescription.
The US Food and Drug Administration recently licensed a new Salk-type injectable polio vaccine ( Poliovirus Vaccine Inactivated - Connaught) that is more potent in its antigenicity than any other inactivated…
Med Lett Drugs Ther. 1988 May 6; 30(765):50-1
The US Food and Drug Administration recently licensed a new Salk-type injectable polio vaccine ( Poliovirus Vaccine Inactivated - Connaught) that is more potent in its antigenicity than any other inactivated polio vaccine (IPV) previously available in the USA. Live oral polio vaccine (OPV) has been the preferred vaccine for routine immunization in the USA since the early 1960's. Its advantages over IPV have included ease of administration, superior immunogenicity, induction of gastrointestinal immunity, increased immunization through spread of vaccine virus to unimmunized susceptible contacts, and lower cost (AM McBean and JF Modlin, Pediatr Infect Dis J, 6:881, 1987).
A new Haemophilus influenzae type b capsular polysaccharide vaccine conjugated with diphtheria toxoid ( ProHIBiT - Connaught) was recently marketed in the USA. It is being promoted as a replacement for older,…
Med Lett Drugs Ther. 1988 Apr 22; 30(764):47-8
A new Haemophilus influenzae type b capsular polysaccharide vaccine conjugated with diphtheria toxoid ( ProHIBiT - Connaught) was recently marketed in the USA. It is being promoted as a replacement for older, unconjugated H. influenzae vaccines ( b- Capsa I ; Hibimune ; HibVAX ) previously reviewed in The Medical Letter (Volume 27, page 61, 1985).